{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(7)"],"submitter":["Zhong WZ"],"pubmed_abstract":["<h4>Purpose</h4>ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.<h4>Methods</h4>From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and <i>EGFR</i>-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["713-722"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8078324"],"repository":["biostudies-literature"],"pubmed_title":["Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial."],"pmcid":["PMC8078324"],"pubmed_authors":["Huang C","Wu L","Ren SX","Yu P","Xu ST","Wu YL","Cheng Y","Li XF","Ma HT","Yang JJ","Wang Q","Liu LX","Yang XN","Wang BH","Li J","Liu SY","Zhou Q","Liu YY","Yin R","Chen C","Yang F","Chen KN","Zhong WZ","Yan HH","Mao WM","Xu S","Xu SD","Wei YC","Liu ZD"],"additional_accession":[]},"is_claimable":false,"name":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.","description":"<h4>Purpose</h4>ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.<h4>Methods</h4>From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and <i>EGFR</i>-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-22T01:30:44.125Z","creation":"2025-04-05T19:58:20.399Z"},"accession":"S-EPMC8078324","cross_references":{"pubmed":["33332190"],"doi":["10.1200/JCO.20.01820"]}}